AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25924855 — intervention group
Group type: EXPERIMENTAL
Intervention: Procera crowns
Number of subjects: 27
Study 25924855 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Press crowns
Number of subjects: 27
Study 25924855 — intervention group
Group type: COMPARATOR
Intervention: Crown therapy (both types)
Number of subjects: 27
Study 23590389 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 1816
Study 23590389 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1816
Study 21762476 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 120
Study 21762476 — intervention group
Group type: COMPARATOR
Intervention: Elastic Stable Intramedullary Nailing (ESIN) with a Titanium Elastic Nail (TEN)
Number of subjects: 120
Study 19863317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically produced wine
Number of subjects: 0
Study 19863317 — intervention group
Group type: COMPARATOR
Intervention: Traditionally produced wine 1
Number of subjects: 0
Study 19863317 — intervention group
Group type: COMPARATOR
Intervention: Traditionally produced wine 2
Number of subjects: 0
Study 17108420 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-side loaded condition (15% body load)
Number of subjects: 21
Study 17108420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-body loaded condition (15% body load)
Number of subjects: 21
Study 17108420 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition
Number of subjects: 21
Study 15611457 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐pressure, nonsequential pneumatic compression sleeves
Number of subjects: 45
Study 15611457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sleeves used)
Number of subjects: 45
Study 12162602 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized calcium (Ca) and phosphorus (P) supplementation adjusted to achieve urinary excretion of > or = 1.2 mmol/L Ca and > or = 0.4 mmol/L P.
Number of subjects: 20
Study 9583766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with pethidine
Number of subjects: 20
Study 9583766 — intervention group
Group type: COMPARATOR
Intervention: Staff-controlled analgesia with pethidine
Number of subjects: 20
Study 7644079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 25 mg
Number of subjects: 187
Study 7644079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 50 mg
Number of subjects: 187
Study 7644079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 187
Study 7644079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 7644079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan
Number of subjects: 187
Study 2787310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 12 cc/kg
Number of subjects: 8
Study 2787310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 14 cc/kg
Number of subjects: 8
Study 2787310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 16 cc/kg
Number of subjects: 8
Study 2787310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 18 cc/kg
Number of subjects: 8
Study 342359 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone capsules (Duogastrone, 50 mg four times a day for six weeks)
Number of subjects: 86
Study 342359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 342359 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone capsules
Number of subjects: 86
Study 31866104 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy for drug abusers (120 days treatment)
Number of subjects: 640
Study 31866104 — intervention group
Group type: COMPARATOR
Intervention: Behaviour therapy for alcohol abusers (90 days treatment)
Number of subjects: 640
Study 31866104 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy for both groups
Number of subjects: 640
Study 30756167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (IH) with FiO2 at 13.5% for 180 minutes
Number of subjects: 123
Study 30756167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (IH) with individually adjusted FiO2 to achieve 80% oxygen saturation for 180 minutes
Number of subjects: 123
Study 30756167 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxic exposure)
Number of subjects: 123
Study 28646811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tui na treatment (2 times/week for 10 weeks, 15 min/session)
Number of subjects: 31
Study 28646811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tui na treatment
Number of subjects: 31
Study 26110296 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole (960 mg twice a day)
Number of subjects: 175
Study 26110296 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg twice a day)
Number of subjects: 175
Study 26110296 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin (250 mg once a day)
Number of subjects: 175
Study 22573730 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 47
Study 22573730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21991740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 80
Study 21991740 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 80
Study 18926729 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg b.d.
Number of subjects: 0
Study 18926729 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50mg b.d.
Number of subjects: 0
Study 18926729 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 17114880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose in addition to standard acetylsalicylic acid/heparin treatment
Number of subjects: 654
Study 15119913 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive clinical environment treatment program
Number of subjects: 175
Study 10850391 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC method for quantification of codeine and its metabolites
Number of subjects: 11
Study 10850391 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotyping using codeine, debrisoquine, and dextromethorphan
Number of subjects: 11
Study 8756971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay at the Dead Sea (1 week)
Number of subjects: 0
Study 8756971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay at the Dead Sea (3 weeks)
Number of subjects: 0
Study 8756971 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay at the Dead Sea
Number of subjects: 0
Study 1581278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard progesterone regimen
Number of subjects: 14
Study 1581278 — intervention group
Group type: EXPERIMENTAL
Intervention: High progesterone regimen
Number of subjects: 14
Study 1581278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low progesterone regimen
Number of subjects: 14
Study 3981625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg orally)
Number of subjects: 0
Study 29958049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g oral NAC
Number of subjects: 17
Study 29958049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 27863843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 362
Study 27863843 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept
Number of subjects: 362
Study 26119263 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal-linguistic mentation
Number of subjects: 138
Study 26119263 — intervention group
Group type: COMPARATOR
Intervention: Mental imagery
Number of subjects: 138
Study 26119263 — intervention group
Group type: COMPARATOR
Intervention: Low trait ruminators (both mentation types)
Number of subjects: 138
Study 24054756 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% isosorbide 5 mononitrate (Group A)
Number of subjects: 55
Study 24054756 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem (Group B)
Number of subjects: 55
Study 24054756 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem + 0.2% isosorbide 5 mononitrate (Group C)
Number of subjects: 55
Study 21711205 — intervention group
Group type: EXPERIMENTAL
Intervention: CCH1
Number of subjects: 90
Study 21711205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19250773 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking at T0 (4-6 weeks postpartum)
Number of subjects: 871
Study 19250773 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking at T1 (6 months postpartum)
Number of subjects: 871
Study 19250773 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking at T2 (12 months postpartum)
Number of subjects: 871
Study 19250773 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse into earlier stages of motivation to quit smoking
Number of subjects: 871
Study 16914594 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human TSH (rhTSH) preparation
Number of subjects: 100000
Study 16914594 — intervention group
Group type: COMPARATOR
Intervention: hypothyroid preparation
Number of subjects: 100000
Study 15273269 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma screening questionnaire administered to parents
Number of subjects: 3067
Study 11093918 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)-receptor antagonists (cimetidine or ranitidine)
Number of subjects: 0
Study 11093918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration
Number of subjects: 0
Study 11093918 — intervention group
Group type: EXPERIMENTAL
Intervention: H(1)-receptor antagonist (mepyramine)
Number of subjects: 0
Study 11093918 — intervention group
Group type: EXPERIMENTAL
Intervention: H(1)- and H(2)-receptor blockade
Number of subjects: 0
Study 9262979 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house 13C-urea breath test
Number of subjects: 110
Study 9262979 — intervention group
Group type: COMPARATOR
Intervention: Commercial 13C-urea breath test
Number of subjects: 110
Study 8471592 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma at 0.1 mg/m2
Number of subjects: 15
Study 8471592 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma at 0.25 mg/m2
Number of subjects: 15
Study 8471592 — intervention group
Group type: COMPARATOR
Intervention: Interferon-gamma at 0.01 mg/m2
Number of subjects: 15
Study 3519353 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergometrin (0.125 mg, 3 times a day for 4 weeks)
Number of subjects: 880
Study 3519353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 3519353 — intervention group
Group type: COMPARATOR
Intervention: Breast-feeding (regardless of Methergin use)
Number of subjects: 880
Study 3042354 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil 60 mg twice daily (adjustable to 30 mg, 60 mg, or 90 mg based on blood pressure response)
Number of subjects: 295
Study 3042354 — intervention group
Group type: COMPARATOR
Intervention: captopril 25 mg twice daily (adjustable to 12.5 mg, 25 mg, or 50 mg based on blood pressure response)
Number of subjects: 295
Study 29220114 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend (TAE) regimen with aflibercept
Number of subjects: 41
Study 29220114 — intervention group
Group type: COMPARATOR
Intervention: Every-other-month (2M) regimen with aflibercept
Number of subjects: 41
Study 28918112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegged glenoid component
Number of subjects: 46
Study 28918112 — intervention group
Group type: COMPARATOR
Intervention: Keeled glenoid component
Number of subjects: 46
Study 25553110 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN therapy
Number of subjects: 140
Study 24458902 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual training program (experimental group)
Number of subjects: 26
Study 24458902 — intervention group
Group type: COMPARATOR
Intervention: Control group (without training)
Number of subjects: 26
Study 21614492 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 34
Study 19216268 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium‐reinforced e‐PTFE membrane and allogeneic bone matrix
Number of subjects: 5
Study 19216268 — intervention group
Group type: COMPARATOR
Intervention: Titanium‐reinforced e‐PTFE membrane and autogenous bone chips
Number of subjects: 5
Study 16584354 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16
Study 16584354 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days)
Number of subjects: 16
Study 16584354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14620495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention households received information about CVD and regular visits by social workers who measured cooking fats and salt and counselled cooks on the goals of intervention.
Number of subjects: 403
Study 14620495 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 403
Study 10896648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 52
Study 10896648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss
Number of subjects: 52
Study 10896648 — intervention group
Group type: COMPARATOR
Intervention: Exercise without weight loss
Number of subjects: 52
Study 10896648 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 8810683 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 227
Study 8810683 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 227
Study 8810683 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR response criteria
Number of subjects: 227
Study 8810683 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR and WHO/ILAR response criteria
Number of subjects: 227
Study 1426505 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 34
Study 1426505 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 1426505 — intervention group
Group type: COMPARATOR
Intervention: parous control group (no gemeprost)
Number of subjects: 34
Study 3914368 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone ointment 0.25%
Number of subjects: 0
Study 3914368 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05%
Number of subjects: 0
Study 30869644 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based treatment program (Tät app) for SUI, 3-month duration focusing on pelvic floor muscle training (PFMT)
Number of subjects: 15
Study 30869644 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based treatment program (Tät app) for SUI
Number of subjects: 15
Study 29574600 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with near complete or complete recanalization (TICI grades 2b and 3)
Number of subjects: 130
Study 29574600 — intervention group
Group type: EXPERIMENTAL
Intervention: Futile recanalization group
Number of subjects: 130
Study 29574600 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis predictors of futile recanalization
Number of subjects: 130
Study 26947217 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 1962
Study 25486269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (various types)
Number of subjects: 1741
Study 25486269 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa equivalent daily dose
Number of subjects: 1741
Study 22562505 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTV training combined with delivery instructions
Number of subjects: 122
Study 22562505 — intervention group
Group type: COMPARATOR
Intervention: Delivery instructions only (Control)
Number of subjects: 122
Study 20542811 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5543
Study 20542811 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 5543
Study 18717174 — intervention group
Group type: EXPERIMENTAL
Intervention: Molloplast B
Number of subjects: 33
Study 18717174 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Reline Soft
Number of subjects: 33
Study 18717174 — intervention group
Group type: EXPERIMENTAL
Intervention: Silagum Comfort
Number of subjects: 33
Study 18717174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mollosil Plus
Number of subjects: 33
Study 15687147 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% resection of the femoral head‐neck junction
Number of subjects: 15
Study 15687147 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% resection of the femoral head‐neck junction
Number of subjects: 15
Study 15687147 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% resection of the femoral head‐neck junction
Number of subjects: 15
Study 15687147 — intervention group
Group type: COMPARATOR
Intervention: Contralateral femoral neck (control)
Number of subjects: 15
Study 11481167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 273
Study 11481167 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 273
Study 9496247 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) at a dosage of 0.5 nmol/kg
Number of subjects: 12
Study 9496247 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1)
Number of subjects: 12
Study 7827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-enriched lupin milk
Number of subjects: 0
Study 7827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin flour bread
Number of subjects: 0
Study 7827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite meals with lupin flour
Number of subjects: 0
Study 7827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin-protein isolate
Number of subjects: 0
Study 7827007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin-milk base
Number of subjects: 0
Study 7827007 — intervention group
Group type: COMPARATOR
Intervention: Soya-bean-milk base
Number of subjects: 0
Study 2917311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen in combination with standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Number of subjects: 100
Study 2917311 — intervention group
Group type: COMPARATOR
Intervention: Standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Number of subjects: 100
Study 2917311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosol steroid receptor determinations
Number of subjects: 100
Study 29621938 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction on the Rey Osterrieth Complex Figure (ROCF)
Number of subjects: 98
Study 29621938 — intervention group
Group type: COMPARATOR
Intervention: Standard format of the Rey Osterrieth Complex Figure (ROCF)
Number of subjects: 98
Study 29621938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (strategy instruction and standard format)
Number of subjects: 98
Study 27734257 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 124
Study 27734257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 27053235 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg ATG (Thymoglobulin)
Number of subjects: 58
Study 27053235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24713613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (high dose selective DA D2/3-receptor antagonist)
Number of subjects: 78
Study 24713613 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 78
Study 23279492 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (0.5 mg/kg) administered at 55 days post-ovulation
Number of subjects: 6
Study 23279492 — intervention group
Group type: COMPARATOR
Intervention: Saline solution administered at 55 days post-ovulation (Control Group)
Number of subjects: 6
Study 19852302 — intervention group
Group type: EXPERIMENTAL
Intervention: Runmushu Oral Liquid (RMS) combined with Hialid eye drops
Number of subjects: 72
Study 19852302 — intervention group
Group type: COMPARATOR
Intervention: Hialid eye drops alone
Number of subjects: 72
Study 17252006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation with subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks
Number of subjects: 67
Study 17252006 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks without intravenous iron
Number of subjects: 67
Study 17252006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation with subcutaneous epoetin beta
Number of subjects: 67
Study 15470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 22
Study 15470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical trainer
Number of subjects: 22
Study 15470311 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climber
Number of subjects: 22
Study 15470311 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 22
Study 11235144 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist with flutamide (n = 5)
Number of subjects: 9
Study 11235144 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist mono-therapy (n = 4)
Number of subjects: 9
Study 9648044 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant use as prescribed (Ritalin)
Number of subjects: 161
Study 9648044 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant use (Ritalin)
Number of subjects: 161
Study 9648044 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant storage policies in schools
Number of subjects: 161
Study 9648044 — intervention group
Group type: EXPERIMENTAL
Intervention: School policies regarding prescription drugs
Number of subjects: 161